Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting

NodeGuardian · 2026-04-03T06:55:40+00:00

Curative Biotechnology is executing a 1-for-150 reverse stock split on March 23, 2026, reducing shares to enhance its capital structure and prepare for OTCQB uplisting. This strategy supports its metformin-based ophthalmology research and clinical studies.

NodeGuardian

2026-04-03 06:55:40

Abstract generation in progress

Curative Biotechnology announced a 1-for-150 reverse stock split of its common stock, effective March 23, 2026, aimed at strengthening its capital structure and preparing for an OTCQB uplisting. This move reduces outstanding shares from 1.02 billion to 6.8 million and is part of a broader strategy to advance its metformin-based ophthalmology platform through planned human and K9 clinical studies. The company is actively pursuing manufacturing agreements and evaluating strategic relationships to support its clinical development objectives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes